Pancreatic enzyme replacement therapy in patients with pancreatic cancer: A national prospective study

ObjectiveUK national guidelines recommend pancreatic enzyme replacement therapy (PERT) in pancreatic cancer. Over 80% of pancreatic cancers are unresectable and managed in non-surgical units. The aim was to assess variation in PERT prescribing, determine factors associated with its use and identify potential actions to improve prescription rates.DesignRICOCHET was a national prospective audit of malignant pancreatic, peri-ampullary lesions or...